RxDoctor Payments Data

Lindsey Bryant, APRN

Psychiatric/Mental Health · Little Rock, ARNPI 1164991048

Payments from drug & device makers

$717in general payments, 2019–2025

Across 15 payments — averaging $47.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$155
  • E.r. Squibb & Sons, L.L.C.$109
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$102
  • Otsuka America Pharmaceutical, Inc.$99
  • Axsome Therapeutics, Inc.$70
  • Novartis$51
  • plus $131 from 4 others

What the payments were for

  • Food & beverage$60885%
  • Education$10915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717 in reported general payments places this provider in the 45th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$146,572
Medicare patients
297
Services billed
1,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole11$32,802
RexultiBrexpiprazole25$28,833
Divalproex Sodium363$17,696
EliquisApixaban21$10,802
Aripiprazole83$7,783
Quetiapine Fumarate266$3,950
Buspirone Hcl188$2,802
Mirtazapine126$2,533
Donepezil Hcl54$1,922
Memantine Hcl56$1,842
Olanzapine79$1,411
Sertraline Hcl173$1,408
RivastigmineRivastigmine Tartrate14$1,131
Escitalopram Oxalate70$1,011
Duloxetine Hcl34$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$99$61,63536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →